New Study Shows Xarelto May Be Twice As Risky When Compared To Warfarin

Since 2011, the U.S. Food and Drug Administration (FDA) has approved the use of the drug Xarelto as a prescription blood thinner, also known as an anticoagulant. Xarelto is a relatively new drug designed to reduce the risk of blood clots in patients undergoing knee or hip replacement surgeries. The drug has also been used to treat deep vein thrombosis (DVT) and pulmonary embolism. The drug has been highly successful for its makers, and has been prescribed more than 11 million times in the United States. Unfortunately, recent studies have linked the use of Xarelto with dangerous side effects.

4 Highlights of the Recent Xarelto Study

One recent study has revealed the true extent of the risk of internal bleeding associated with Xarelto use. The risk of this bleeding is severe, with some cases leading to death. Highlights from the study include the following:

• The study was published in the British Medical Journal.
• The study included more than 45,000 patients who have used Xarelto, also known as rivaroxaban, its generic name.
• The study assessed the overall safety of Xarelto use when compared with warfarin, also known as Coumadin, the most commonly used blood-thinning medication to date.
• The study found that there is a twofold higher risk of bleeding associated with the use of rivaroxaban as compared with the use of warfarin.

If you took Xarelto and suffered harm as a result, you may be entitled to compensation. To learn more, we encourage you to reach out today.